Printer Friendly

ImaRx PHARMACEUTICAL CORP. FILES SUIT AGAINST MOLECULAR BIOSYSTEMS INC. OVER TRADE SECRETS

 TUCSON, Ariz., July 1 /PRNewswire/ -- ImaRx Pharmaceutical Corp. (ImaRx), a biotechnology company based in Tucson, has filed suit in federal court against Molecular Biosystems Inc. (NYSE: MB) of San Diego.
 The suit charges Molecular Biosystems (MBI) with misappropriation of trade secrets, breach of contract, breach of fiduciary duty, and unfair competition.
 The allegations stem from a visit by Molecular Biosystems Chief Executive Officer Kenneth Widder and another MBI employee to ImaRx facilities on Dec. 11, 1990. ImaRx contends that following the visit, Molecular Biosystems disclosed and used confidential ImaRx information regarding diagnostic contrast agents and certain proposed trademarks, in violation of a confidentiality agreement. The suit alleges that Molecular Biosystems went so far as to file a patent application in February 1991 and trademark applications in May 1992 based on ImaRx's confidential information. ImaRx is seeking damages as well as dismissal of MBI's patent.
 "Based on the evidence that has surfaced to date, we believe this to be a most egregious case," said ImaRx attorneys Suzanne Miller and Albert Preston of Woodcock Washburn Kurtz Mackiewicz & Norris in Philadelphia.
 The suit against Molecular Biosystems was filed in U.S. District Court in Tucson. At ImaRx's request, the U.S. Patent Office also recently reviewed ImaRx's earlier filed patent application and the later filed MBI patent, and determined that a conflict does exist between the two. The Patent Office will conduct a patent interference proceeding to determine whether to dismiss MBI's patent.
 ImaRx Pharmaceutical Corp. was founded in 1990 by Dr. Evan C. Unger to develop products for use as therapeutics and in medical diagnostic imaging. The current litigation involves one of Unger's developments in the diagnostic imaging field. In addition to serving as the president and chief executive officer of ImaRx, Unger is also the director of Magnetic Resonance Imaging and Computed Tomography at the University of Arizona in Tucson. He is a well-known researcher and lecturer in the field of diagnostic imaging, and has many patents and publications to his credit.
 Details on the litigation may be obtained by contacting Suzanne E. Miller, Albert W. Preston, or Francis A. Paintin of Woodcock Washburn Kurtz Mackiewicz & Norris, One Liberty Place, 46th Floor, Philadelphia, Pa. 19103.
 ImaRx Pharmaceutical Corp. designs, develops and markets advanced diagnostic agents for the imaging industry. ImaRx is a privately held Arizona corporation with its founding researchers and clinicians as its major stockholders.
 /delval/
 -0- 7/1/93
 /CONTACT: Thomas Fritz of ImaRx Pharmaceutical Corp., 602-770-1259, or Kathy Loehrig or Linda Pollock of Anne Klein & Associates, 609-778-0380, for ImaRx Pharmaceutical Corp./


CO: ImaRx Pharmaceutical Corp.; Molecular Biosystems Inc. ST: California, Arizona IN: MTC SU:

MP -- PH010 -- 7624 07/01/93 10:28 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 1, 1993
Words:445
Previous Article:CABLE COMPANIES TO MAKE REFUNDS UNDER AGREEMENT WITH PREATE
Next Article:NATIONSBANK COMPLETES ACQUISITION OF CHICAGO RESEARCH AND TRADING GROUP
Topics:


Related Articles
MOLECULAR BIOSYSTEMS ANNOUNCES LICENSE OF ITS ANTISENSE PATENTS
IMARX AND DUPONT MERCK ENTER INTO LICENSING AGREEMENT
Pharmacopeia, PE Biosystems and Becton, Dickinson Collaborate to Advance High-Throughput Screening Technology.
Maxygen Initiates Arbitration Against Energy BioSystems.
ImaRx Therapeutics to Collaborate With Genzyme on Gene Delivery; Localized Expression of Non-Viral Vectors Enhanced With Microbubble & Ultrasound.
Ambion Signs Armored RNA(R) Licensing Agreement With Celera Diagnostics.
SRU Biosystems Denies Patent Infringement Claim.
Thomas Weisel Partners Hosts Annual Healthcare Conference; - Investment conference will focus on healthcare trends -.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters